title: Treatment of juvenile idiopathic arthritis in the biologic age.
abstract: Before the biologic era, treatment of juvenile idiopathic arthritis (JIA) was often highly unsatisfactory, with children forced to endure the ill effects of lifelong disease, including pain and stiffness, disability, and even increased risk of mortality. Thanks in large part to improved understanding of the underlying pathophysiology of the disease, multiple new biologic agents have been developed and applied to these disorders, with remarkable effects. However, much information remains to be learned about applying particular therapies to the distinct categories of JIA, and there is still considerable room for improvement in individual patients.
authors.affiliation: Department of Pediatrics, University of Alabama at Birmingham, CPP N210M, 1600 7th Avenue South, Birmingham, AL 35233, USA. Electronic address: mstoll@peds.uab.edu.
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Stoll
authors.forename: Randy Q
authors.initials: RQ
authors.lastname: Cron
mesh_terms: D000069594:Abatacept; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D000068800:Etanercept; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab; D012460:Sulfasalazine / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000093242:Interleukin-6 Inhibitors
chemical_list: D000069594:Abatacept; D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000068800:Etanercept; D018796:Immunoconjugates; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D007555:Isoxazoles; D000077339:Leflunomide; D008727:Methotrexate; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D012460:Sulfasalazine; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C541220:canakinumab; C531377:rilonacept; C502936:tocilizumab
keywords: Biologic therapy; Juvenile idiopathic arthritis; Randomized trials; Treatment